

# Synthesis in Drug Discovery and Development

## Programme Themes and Features

The three main themes of the symposium will be:

- Innovative synthesis facilitating candidate discovery
- Novel bioisosteres and methodology applicable to drug discovery
- Overcoming challenges of scale-up and process scale chemistry

## Who should attend

Chemists from industry and academia, including synthetic, medicinal and process chemists.

## Registration and Students

Registration is open and fees include attendance at both afternoon sessions.

- £60 RSC member
- £100 Non-member
- £25 RSC student\* member
- £37 Student\* non-member

\*Student means undergraduate or post-graduate, not post-doc.

## Exhibition Opportunities

We are offering two alternative packages to our valued supporters:

- Exhibitor Sponsorship Package, charged at £60
- Speaker Sponsorship Package, charged at £120

Full details of both packages may be found on the event website. Both packages exclude any delegate registration.

## Sponsorship

We are grateful to our confirmed sponsors and additional sponsors are sought to support the low registration fees offered to student attendees.

## Secretariat Contact

Maggi Churchouse, +44 (0)1359 221004  
maggi@maggichurhouseevents.co.uk

## Websites

<https://www.maggichurhouseevents.co.uk/bmcs>  
also <https://rscbmcs.org/events>

## Organising Committee

Nadia Ahmad, Charles River  
Duncan Hay (Chairman), Vertex  
Martin Swarbrick (Treasurer),  
Cancer Research UK  
Andrew Williams, Hon Chairman,  
RSC BMCS



## Call for Posters

Applications are invited for poster presentation. Posters will be displayed throughout both days and applicants are asked if they wish to provide a two-minute flash oral presentation when submitting their abstracts. The closing date for submission is 30th January.

# Second Announcement and Call for Posters

*Celebrating Synthesis:  
the Heart of Drug Discovery  
and Development*

**NOW  
Virtual!**

# Synthesis in Drug Discovery & Development

Monday & Tuesday, 22<sup>nd</sup> & 23<sup>rd</sup> March 2021

*A Virtual Symposium*



# Synthesis in Drug Discovery and Development

## Synopsis

Synthesis is at the heart of drug discovery and development. The industry has increasingly demanded higher quality clinical candidates and has sought to exploit less druggable biological targets. Densely functionalised small molecules with a high degree of synthetic complexity are often the result of these demands. Successful programmes therefore require the application of innovative synthesis in all stages of discovery and development. The medicinal chemist's toolbox is also enhanced by the introduction of novel bioisosteres, often made available only through the application of new synthetic methods. This symposium aims to celebrate the crucial role of synthesis in the success of drug discovery and development.

## Programme

### Monday, 22nd March 2021

- 13.00 *Opening remarks*  
**Duncan Hay**, Vertex  
*Session chair: Martin Swarbrick*, Cancer Research UK
- 13.05 *Innovative synthetic methods and their application to the discovery of ATAD2 inhibitors*  
**Carine Guérot**, AstraZeneca
- 13.45 *Discovery, application and conformational bias of aryl 3-oxabicyclo[4.1.0]heptanes, non-nitrogen containing bioisosteres of N-aryl morpholines*  
**Heather Hobbs**, GlaxoSmithKline
- 14.25 *Bioisosteric replacements and scale-up challenges in drug discovery*  
**Thomas Fessard**, SpiroChem
- 15.05 Refreshment break  
*Session chair: Nadia Ahmad*, Charles River
- 15.20 Flash poster presentations - part 1
- 15.35 *Development and application of facile and flexible 2+2+2 cyclo-trimerisation methodology and its impact on two lead identification programmes*  
**Simon Peace**, GlaxoSmithKline
- 16.15 *New synthetic chemistry for the exploration of 3-D pharmaceutical space*  
**Peter O'Brien**, University of York
- 16.55 Closing remarks
- 17.00 Close



#SDDD21

# Synthesis in Drug Discovery and Development

## Programme (continued)

### Tuesday, 23rd March 2021

- 13.00 *Opening remarks*  
**Duncan Hay**, Vertex  
*Session chair: Katherine Jones*, GlaxoSmithKline
- 13.05 *Synthesis of new chemical motifs as design options for drug discovery*  
**James Bull**, Imperial College London
- 13.45 *Glucose responsive insulin - synthesis enabling discovery and development*  
**Paul Bulger**, MSD
- 14.25 *Modern organic synthesis in the discovery of chemical probes for new targets*  
**Paul Brennan**, Structural Genomics Consortium
- 15.05 Refreshment break  
*Session chair: Andrew Williams*, Honorary Chairman of the RSC BMCS
- 15.20 Flash poster presentations - part 2
- 15.35 *Sp<sup>3</sup>-rich cyclic hydrazine frameworks for drug discovery*  
**Mike Shipman**, University of Warwick
- 16.15 *A 3-way BET to scale up a trans-disubstituted dihydrobenzofuran active bromodomain inhibitor*  
**Catherine Alder**, GlaxoSmithKline
- 16.55 Closing remarks
- 17.00 Close

AstraZeneca 

  
charles river

 evotec

 MSD

Supported by:  EUROPEAN FEDERATION FOR MEDICAL CHEMISTRY AND CHEMICAL BIOLOGY

 RSC INTEREST GROUP  
BIOLOGICAL AND MEDICAL  
CHEMISTRY SECTOR